Danaher Corporation (BVMF:DHER34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 733.03B -4.2% |
| Revenue (ttm) | 129.69B +4.6% |
| Net Income | 20.68B +17.3% |
| EPS | 29.10 +19.6% |
| Shares Out | n/a |
| PE Ratio | 35.44 |
| Forward PE | 22.98 |
| Dividend | 0.17 (0.46%) |
| Ex-Dividend Date | Jun 25, 2026 |
| Volume | 352 |
| Open | 36.56 |
| Previous Close | 36.13 |
| Day's Range | 36.56 - 37.20 |
| 52-Week Range | 28.02 - 46.06 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 21, 2026 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial numbers in USD Financial StatementsNews
Danaher names Julie Sawyer Montgomery as CEO
Danaher (DHR) announced that the company’s Board of Directors has appointed Julie Sawyer Montgomery as President and CEO and a member of the Board of Directors, effective October 1. On…
Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer
Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer ...
Danaher’s recent volatility presents buying opportunity, says Argus
Argus keeps a Buy rating on Danaher (DHR) with a price target of $230 but notes that the recent trading volatility in the shares presents a buying opportunity. The company…
Danaher price target lowered to $240 from $250 at Deutsche Bank
Deutsche Bank analyst Justin Bowers lowered the firm’s price target on Danaher (DHR) to $240 from $250 and keeps a Buy rating on the shares following the Q2 report. Published…
Danaher price target lowered to $230 from $270 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on Danaher (DHR) to $230 from $270 and keeps a Buy rating on the shares. Overall total-company numbers were “fine” to…
Danaher price target lowered to $236 from $240 at TD Cowen
TD Cowen lowered the firm’s price target on Danaher (DHR) to $236 from $240 and keeps a Buy rating on the shares. The firm updated its model following Q2 results…
Danaher price target raised to $215 from $200 at RBC Capital
RBC Capital raised the firm’s price target on Danaher (DHR) to $215 from $200 and keeps an Outperform rating on the shares after its Q2 earnings beat. The firm’s rating…
Danaher price target lowered to $220 from $260 at Stifel
Stifel analyst Daniel Arias lowered the firm’s price target on Danaher (DHR) to $220 from $260 and keeps a Buy rating on the shares. While the headline numbers for Q2…
Danaher price target lowered to $200 from $235 at Guggenheim
Guggenheim lowered the firm’s price target on Danaher (DHR) to $200 from $235 and keeps a Buy rating on the shares after updating estimates following earnings and meeting with the…
Danaher price target lowered to $195 from $212 at Wells Fargo
Wells Fargo lowered the firm’s price target on Danaher (DHR) to $195 from $212 and keeps an Equal Weight rating on the shares. If the Bioprocess order push-out is simply…
Don't Quit on Danaher Stock After Horrific Earnings Reaction
There's reason to believe the stock can stage a comeback after its worst day in two decades.
Danaher Stock (DHR) Is Down 13% and Suffering Its Worst Decline in 30 Years. Here’s Why
The company makes medical diagnostic equipment.
Bio-Rad slips as Sartorius weighed on by Danaher bioprocessing unit miss
Sartorius (SSSGY) shares are trading lower in Europe after earnings from competitor Danaher (DHR), including bioprocessing unit results that missed expectations. Bio-Rad Laboratories (BIO), which owns...
Danaher's revenue outlook cut, biotech miss overshadow profit forecast raise
Danaher raised its annual profit forecast on Tuesday, but shares fell nearly 12% in premarket trading after the life sciences firm trimmed its core revenue growth outlook and reported weaker-than-exp...
Danaher Earnings Call Transcript: Q2 2026
Q2 saw better-than-expected revenue, earnings, and cash flow, with strong life sciences and diagnostics performance. Raised full-year core revenue and EPS guidance, closed Masimo acquisition early, and saw robust order growth despite bioprocessing shipment delays.
Danaher Quarterly report: Q2 2026
Danaher has published its Q2 2026 quarterly earnings report on July 21, 2026.
Danaher Earnings release: Q2 2026
Danaher released its Q2 2026 earnings on July 21, 2026, summarizing the period's financial results.
Danaher Slides: Q2 2026
Danaher has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Danaher reports Q2 adjusted EPS $1.94, consensus $1.84
Reports Q2 revenue $6.27B, consensus $6.14B. Rainer M. Blair, President and Chief Executive Officer, stated, “We delivered a better than expected second quarter, with core growth improving versus the ...
Danaher sees Q3 non-GAAP core revenue up 2%-3% y/y
06:01 EDT Danaher (DHR) sees Q3 non-GAAP core revenue up 2%-3% y/y
Danaher sees FY26 non-GAAP core revenue up 3%-4% y/y
06:01 EDT Danaher (DHR) sees FY26 non-GAAP core revenue up 3%-4% y/y
Danaher Reports Second Quarter 2026 Results
WASHINGTON, July 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the second quarter 2026. All results in this release reflect only continuing operations and period...
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...